medical

President Donald Trump gestures during a law enforcement leaders dinner in the Rose Garden at the White House in Washington, D.C., on Monday, the same day the White House announced his annual medical evaluations have been scheduled for May 26. Photo by Aaron Schwartz/UPI | License Photo

May 11 (UPI) — President Donald Trump‘s annual dental and medical evaluations are scheduled for May 26, the White House announced on Monday evening.

At 79, Trump is the second-oldest person to serve as president and was the oldest to be sworn into a new term. Questions about his health and mental fitness that surfaced during his first administration have intensified since he returned to the White House last year amid reports and images that appear to show him falling asleep during public events, as well as makeup covering apparent bruises on his hands.

The evaluations are to be conducted at Walter Reed National Military Medical Center in Maryland, the White House said, stating it is part of Trump’s “regular preventive healthcare.”

Trump frequently boasts about his physical health and mental acuity amid questions about whether his age could affect his ability to carry out the duties of his office.

In October, Trump underwent what administration officials initially described as “a routine yearly check-up,” which would have been his second in six months.

After the examination, Navy Capt. Sean Barbabella, physician to the president, said Trump “remains in exceptional health” following what he called “a scheduled follow-up evaluation.”

The White House said that while in Maryland for the annual evaluations, Trump will “spend time with service members and staff at Walter Reed in recognition of their service, professionalism and dedication to the nation.”

The Trump administration’s historic move to reclassify state-licensed medical marijuana as a less-dangerous drug was cheered by some advocates but for others, it fell far short for the thousands still incarcerated on federal cannabis-related convictions.

The executive order, which acting Atty. Gen. Todd Blanche signed Thursday, does not address current penalties for possessing and selling marijuana or those jailed with yearslong sentences.

“While this is a victory, the fight is far from over,” said Jason Ortiz, director of strategic initiatives for the Last Prisoner Project, a nonprofit focused on cannabis criminal justice reform.

Proponents of legalizing marijuana as well as overhauling prison sentencing say this order, which does not completely decriminalize the drug, benefits only cannabis researchers, growers and others in Big Weed. Meanwhile, thousands — many of whom are people of color — are stuck serving harsh sentences for marijuana-related offenses. Or they have served their time but having a conviction on their record has made life difficult.

Now, advocates are calling on Congress and state lawmakers to take concrete steps to ensure those with marijuana-related convictions receive fair treatment or be forgiven altogether.

Prisoners and their families look for hope

Blanche’s order reclassifies state-licensed medical marijuana as a less-dangerous drug. The major policy shift, which both Presidents Obama and Joe Biden had considered, means cannabis won’t be grouped with drugs like heroin.

But it does not legalize marijuana for medical or recreational use. It shifts licensed medical marijuana from Schedule I — reserved for drugs without medical use and with high potential for abuse — to the less strictly regulated Schedule III. This will likely give licensed medical marijuana operators and cannabis researchers a major tax break and less stringent barriers to doing normal business.

Virtually no one imprisoned at the federal level is there solely for marijuana possession. But many are there for large-scale possession, trafficking offenses or both.

Hector Ruben McGurk, 66, has been serving life without the possibility of parole since 2007 for transporting thousands of pounds of marijuana and money laundering. He is currently imprisoned in Beaumont, Texas, over 800 miles from his son’s El Paso home. His incarceration has been hard on his son, said McGurk’s daughter-in-law, Ferna Anguiano. And the distance makes visits logistically difficult.

So it’s tempting to see this order as a glimmer of hope, given that the family believes McGurk’s punishment far outweighs his crimes. But Anguiano has no idea how to navigate lobbying for his release.

“His release date is death,” Anguiano said. “I mean, we see all this stuff on the news — bigger cases, fatal cases — and people are going in and out of prison and coming out to their families.”

They try to keep in touch through phone calls and a prison texting service. They’re concerned about McGurk’s health and his diabetes management. It would be a dream come true for him to come home.

“He deserves a second chance,” Anguiano said. “Yes, it was a poor decision he did in his lifetime. He was younger. But he is not a bad person. I think it’s fair to say he has served enough time for it.”

It’s not clear whether punishments would be different had marijuana always been scheduled differently, drug policy experts say.

“In addition to schedule-specific penalties, there are marijuana-specific penalties that have nothing to do with the schedule,” said Cat Packer, director of drug markets and legal regulation at the nonprofit Drug Policy Alliance. “Even if marijuana were to be moved to Schedule V, those criminal penalties would still exist and there are mandatory minimums for simple possession.”

Racial disparities exist in convictions and Big Weed

Destigmatizing marijuana has long been an issue for both political parties. Obama commuted the sentences of about 1,900 federal prisoners, almost all of whom were incarcerated for nonviolent drug crimes. Biden pardoned 6,500 people convicted of use and simple possession of marijuana on federal lands and in the District of Columbia. President Trump’s administration has taken far fewer drug clemency actions and does not have an overarching policy directing such actions.

“What many people on the right and the left would like is to move marijuana from this ‘just as bad as heroin’ category and to just sort of de-schedule it entirely,” said Marta Nelson, director of sentencing reform at the Vera Institute of Justice. “Regulate it like you do alcohol or tobacco.”

Studies show Black Americans are roughly 3.7 to 4 times more likely to be arrested for marijuana possession than white Americans, despite usage rates being roughly the same across racial groups. Federal-level marijuana cases are pretty small today, but those serving sentences for federal drug offenses are overwhelmingly Hispanic and Black, according to Justice Department and Bureau of Justice Statistics data.

The racial disparity with drug convictions is reminiscent of 2010 legislation Obama signed reducing the gap between mandatory sentences for crack cocaine versus powder cocaine. In 2018, Trump made it apply retroactively.

Because business owners with state medical marijuana licenses are predominantly white, the tax relief created by the rescheduling will also likely give a leg up to mostly white businesses, Packer said. A lot of equity programs won’t apply.

“This is going to, in my mind, widen the gap, the financial disparities, the business disparities that currently exist between Black and brown, Latino and white owners in the cannabis industry because licenses were not distributed equitably,” Packer said.

Possible next steps for marijuana convictions

In theory, Trump could issue a blanket pardon like he did for Jan. 6 rioters. But Nelson thinks that is highly doubtful.

“Having marijuana convictions on the record for things like mass immigration enforcement is helpful to the administration,” Nelson said.

An impactful next step would be for Congress to outline very comprehensive legislation addressing existing marijuana-related convictions, expungements and industry regulations, she added.

The Last Prisoner Project and other organizations are planning to renew a dialogue with federal lawmakers, including the Congressional Cannabis Caucus, which includes Democratic Rep. Ilhan Omar of Minnesota and Republican Rep. David Joyce of Ohio. They will also continue to lobby for Trump to conduct a large-scale act of commutation and clemency.

Advocates are also hoping Trump’s order will prompt every state to rethink their marijuana classification and penalties.

“It is imperative that every state review their situation, as a lot of their controlled substances at the state level are tied to the federal government,” Ortiz said. “We’re gonna see other states that are going to need a little help from the public to remind them what the right thing to do is.”

Tang writes for the Associated Press.

WASHINGTON — President Trump’s acting attorney general on Thursday signed an order reclassifying state-licensed medical marijuana as a less-dangerous drug, a major policy shift long sought by advocates who said cannabis should never have been treated like heroin by the federal government.

The order signed by Todd Blanche does not legalize marijuana for medical or recreational use under federal law. But it does change the way it’s regulated, shifting licensed medical marijuana from Schedule I — reserved for drugs without medical use and with high potential for abuse — to the less strictly regulated Schedule III. It also gives licensed medical marijuana operators a major tax break and eases some barriers to researching cannabis.

The Trump administration also said it was jump-starting the process for reclassifying marijuana more broadly, setting a hearing to begin in late June.

Trump told his administration in December to work as quickly as possible to reclassify marijuana. On Saturday, as the Republican president signed an unrelated executive order about psychedelics, he seemed to express frustration that it was taking so long.

Blanche said Thursday that the Department of Justice was “delivering on President Trump’s promise” to expand Americans’ access to medical treatment options. “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,” he said in a statement.

What the marijuana reclassification order does

Blanche’s action largely legitimizes medical marijuana programs in the 40 states that have adopted them. It sets up an expedited system for state-licensed medical marijuana producers and distributors to register with the U.S. Drug Enforcement Administration.

It makes clear that cannabis researchers won’t be penalized for obtaining state-licensed marijuana or marijuana-derived products for use in their work, and it grants state-licensed medical marijuana companies a windfall by allowing them, for the first time, to deduct business expenses on their federal taxes.

Any marijuana-derived medicine approved by the Food and Drug Administration is similarly listed in Schedule III, it said.

Since 2015, Congress has prohibited the Justice Department from using its resources to shut down state-licensed medical marijuana systems. But the order nevertheless represents a major policy shift for the U.S. government, which has continued its long-standing marijuana prohibition — dating to the Marihuana Tax Act of 1937 — even as nearly all the states have approved cannabis use in some form.

Two dozen states plus Washington, D.C., have authorized adult recreational use of marijuana, 40 have medical marijuana systems, and eight others allow low-THC cannabis or CBD oil for medical use. Only Idaho and Kansas ban marijuana outright.

The regulation of medical marijuana has come a long way since California became the first state to adopt it in 1996, Blanche wrote.

“Today the vast majority of States maintain comprehensive licensing frameworks governing cultivation, processing, distribution, and dispensing of marijuana for medical purposes,” Blanche wrote. “Taken as a whole, they demonstrate a sustained capacity to achieve the public-interest objectives … including protecting public health and safety and preventing the diversion of controlled substances into illicit channels.”

The president of the American Trade Assn. for Cannabis and Hemp, Michael Bronstein, called it “the most significant federal advancement in cannabis policy in over 50 years.”

“This action recognizes what Americans have long known, cannabis is medicine,” he said in a written statement.

Critic calls the order ‘a tax break to Big Weed’

The Trump administration’s decision drew derision from marijuana legalization opponent Kevin Sabet, the chief executive of Smart Approaches to Marijuana. Sabet said that while marijuana research is necessary, “there are many ways to increase our knowledge without giving a tax break to Big Weed and sending a confusing message about marijuana’s harms to the American public.”

“With this move, we are now confronted with the most pro-drug administration in our history,” Sabet said in a text message. “Policy is now being dictated by marijuana CEOs, psychedelics investors, and podcasters in active addiction.”

Marijuana or marijuana-derived products that are not distributed through a state medical marijuana program will continue to be classified in Schedule I.

Schedule III drugs are defined as having moderate to low potential for physical and psychological dependence. Some critics of the industry have suggested that legalization in the states has led to stronger and stronger cannabis products, which need to be researched rather than categorized less strictly than before.

The efforts to reclassify marijuana

The Justice Department under President Biden had proposed to reclassify marijuana, eliciting nearly 43,000 formal public comments. The DEA was still in the review process when Trump succeeded Biden, and Trump ordered that process to move along as quickly as legally possible.

Blanche’s order sidestepped the review process by relying on a provision of federal law that allows the attorney general to determine the appropriate classification for drugs that the U.S. must regulate pursuant to an international treaty.

It was unclear how the order might affect operations in states where licensed recreational marijuana shops also sell to medical patients. In Washington state, which in 2012 became one of the first states to legalize the adult use of marijuana, 302 of 460 licensed stores have endorsements allowing them to sell tax-free cannabis products to registered patients.

Many Republicans oppose loosening marijuana restrictions. More than 20 Republican senators, several of them staunch Trump allies, signed a letter last year urging the president to keep the current standards.

Trump has made his crusade against other drugs, especially fentanyl, a feature of his second term, ordering U.S. military attacks on Venezuelan and other boats the administration insists are ferrying drugs. He signed another executive order declaring fentanyl a weapon of mass destruction.

Richer and Johnson write for the Associated Press. Johnson reported from Seattle.

It felt like the Olympics. Crowds cheering. The American flag standing tall above the bleachers. Trainers jumping with anticipation. A swimmer staring in disbelief at the clock after his final stroke. The Jumbotron announced: Kristian Gkolomeev — 20.89 seconds. A new world record in the 50-meter freestyle.

Well, kind of.

I’ve left out some details. There was only one swimmer. The crowd? Just doctors, trainers and filmmakers. This was not in an Olympic city nor an Olympic year, but in Greensboro, N.C., in 2025. And there were no iconic rings on the banners, just “Enhanced Games.”

Yes, Gkolomeev swam faster than César Cielo, the official record holder at the time (20.91 seconds). But he did it “enhanced” — a polite way to say that he used performance-enhancing drugs. At the Enhanced Games, doping isn’t punished. It’s required.

The concept, as described by the organization: “to create the definitive scientific, cultural and sporting movement that safely evolves mankind into a new superhumanity.”

Backed by investors such as Peter Thiel and Donald Trump Jr.’s 1789 Capital, the Enhanced Games embodies a techno-utopian ideal: athletes as canvases for chemical optimization, testing the limits of human health for a lot of money. Gkolomeev earned $1 million for his record.

So far, the competition has happened at one-off pop-up events. But in May, Las Vegas will host the first full-scale Enhanced Games, a four-day meet in swimming, track and field, and weightlifting. The group advertises a “potential prize purse of $7.5 million for just a single day of competition,” plus appearance fees.

Does it need to be said? Apparently yes: The Enhanced Games glorifies the risky use of enhancement drugs.

Steroids can harden arteries, elevate stroke risk, damage the liver and permanently alter hormone systems. They are not electrolyte tablets or a little preworkout creatine. If Lance Armstrong had been rewarded — rather than sanctioned — for doping, what would have happened to competitive cycling?

Fans — and especially kids — mimic their idols. As risky as the drugs are for athletes at the Enhanced Games, with its “medical commission” to give the illusion of safety, the substances are even more dangerous when used by people without medical supervision.

The games also expose the economic neglect that drives athletes toward such competition. As Benjamin Proud, the British silver medalist who recently joined the Enhanced Games, put it: “It would have taken me 13 years of winning a World Championship title in order to win what I could win in one race at these games.”

Indeed, the Enhanced Games might look like an easy way out. Only nine swimmers worldwide received prize money and performance bonuses above $75,000 in 2025, according to World Aquatics.

Investors clearly hope to make money off the games as well. The organization is moving closer to becoming a publicly traded company. The economics are not mysterious.

But the Enhanced Games are not just another sporting event. They are an arena for biomedical experimentation and should be regulated as such. The games should face limits similar to those imposed on other high-risk industries, including age restrictions and strict advertising rules.

We already know how to govern legal, profitable activities that carry serious health risks.

In the United States, that means oversight from the Food and Drug Administration and the Federal Trade Commission — bodies that regulate drug protocols and police misleading commercial claims. A steroid-based competition should not be treated as a sport but as a medical experiment and a marketing stunt.

Regulations on pharmaceutical advertising offer a useful model for the Enhanced Games. Prescription drugs are advertised every night on television, but only under strict rules. They require fair balance (content must present benefits and risks with comparable prominence, readability and duration) and a “major statement” of risks (most serious risks must be spoken aloud and not obscured by visuals or music).

Right now, when you play Gkolomeev’s “world-record” video on YouTube, a medical-risk warning appears for barely five seconds — then vanishes. If a cholesterol drug must audibly warn viewers of stroke risk, why shouldn’t a steroid-based competition do the same?

Enhanced Games content should be accompanied by clear warnings of the risks of performance-enhancing drugs and be clearly labeled, age-gated and distributed as high-risk content more akin to pornography than to a boxing match.

Prohibition is not the answer. Trying to shut down these games only fuels a controversy-driven brand. Just recently, the Enhanced Games sued organizations such as World Aquatics and the World Anti-Doping Agency, alleging antitrust violations and that blocking athletes from participating at the Enhanced Games is illegal. As those organizations fight back, they will be seeking to protect the integrity of mainstream sports, but they will also inadvertently be promoting the Enhanced Games.

If we want kids to admire clean athletes rather than those using banned drugs, the Las Vegas launch must not reach the world as a Super Bowl would. The Enhanced Games should not be televised or allowed to stream online to minors. Otherwise, Las Vegas, in May, risks becoming an unregulated public-health experiment mislabeled as a sporting event.

Fabricio Ramos dos Santos is a lawyer, entrepreneur and sports investor.

A BRIT rock back have been forced to cancel an impending gig after an “unexpected medical situation”.

Enter Shikari were due to play a gig at Dublin Academy in Ireland this evening but have been forced to withdraw.

The band kept details sparse but confirmed a “medical reason” was behind their decision to pull the plug on the gig in the Irish capital city.

Issuing a statement, the band revealed they were gutted to be unable to complete the concert as planned.

The band said: “Due to a medical situation both unexpected and beyond our control, we’re sad to have to say we’re having to postpone tonight’s Dublin Academy show.

“If you know anything about us, you know that cancelling/postponing shows is always the absolute last resort once all other options have been exhausted, especially at this short notice.

“We’re very sorry for any inconvenience this causes anyone.

“We’re in conversation with our Irish promoter and will immediately start looking at potential date to reschedule to.

“Thank you in advance for your understanding, and we hope we can see you as soon as possible. ES x.”

Their fans were quick to issue their well-wished amid the uncertain situation.

One penned: “Sending you guys so much love hope you’re all ok.”

Another went on to write: “Hope all is ok – let us know when you’re planning to be back in Ireland!”

A third then said: “Absolutely gutted as flew here solo from Brighton especially *but* sending everyone so much love and hope, and thank you for still being the reason I finally visited Ireland!”

Before a fourth commented: “Sending love as this can’t have been an easy decision, get well soon.”

Whilst a fifth comment read: “Health first always. Hope all is ok. We go again even harder on the rescheduled show to make up for this. Grá mór.”

The band were first formed in 1999 and adopted their current identity in 2003.

Their debut album, Take to the Skies, was eventually released in 2007 and reached number four on the UK Albums Chart.

Their seventh record, released in 2023, became their first chart-topper.

The group’s latest record, surprise released earlier this month, managed to chart at number 16.